Please use this identifier to cite or link to this item: http://hdl.handle.net/123456789/1903
Full metadata record
DC FieldValueLanguage
dc.contributor.authorArora, Shefali-
dc.contributor.authorAgarwal, Shilpi-
dc.contributor.authorSinghal, Shailey-
dc.date.accessioned2015-03-13T08:07:44Z-
dc.date.available2015-03-13T08:07:44Z-
dc.date.issued2014-
dc.identifier.citationInternational Journal of Pharmacy and Pharmaceutical Sciences, Vol 6, Issue 9, 2014en_US
dc.identifier.issn0975-1491-
dc.identifier.urihttp://hdl.handle.net/123456789/1903-
dc.description.abstractThere have been tremendous development in the chemotherapy of cancer and researches are still developing new and more effective drugs to combat this disease. Thiosemicarbazides and thiosemicarbazone possess a wide range of biological applications. This key biological role is often related with their capability to inhibit the enzyme ribonucleotide reductase, similar to what is observed with potent anticancer drugs such as triapine and methisazone. Recent studies have revealed that thiosemicarbazones can inhibit topoisomerase II enzyme. This review discusses current advances of an emerging ‘new wave’ of thiosemicarbazide/thiosemicarbazone and their metal complexes as potent anticancer agents, mode of action and toxicity caused by them.en_US
dc.subjectMedical Scienceen_US
dc.titleAnticancer Activities of Thiosemicarbazides/Thiosemicarbazones: A Reviewen_US
dc.typeArticleen_US
Appears in Collections:Published papers

Files in This Item:
File Description SizeFormat 
review.pdf356.13 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.